These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20602718)

  • 21. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
    Perahia DG; Pritchett YL; Desaiah D; Raskin J
    Int Clin Psychopharmacol; 2006 Nov; 21(6):311-7. PubMed ID: 17012978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.
    Beard SM; McCrink L; Le TK; Garcia-Cebrian A; Monz B; Malik RA
    Curr Med Res Opin; 2008 Feb; 24(2):385-99. PubMed ID: 18157921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs.
    Dworkin RH; Malone DC; Panarites CJ; Armstrong EP; Pham SV
    J Pain; 2010 Apr; 11(4):360-8. PubMed ID: 19853529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States.
    Yang M; Qian C; Liu Y
    Pain Med; 2015 Nov; 16(11):2075-83. PubMed ID: 26118704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain.
    Sun P; Zhao Y; Zhao Z; Bernauer M; Watson P
    Pain Pract; 2012 Nov; 12(8):641-8. PubMed ID: 22335435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
    Matsuoka H; Makimura C; Koyama A; Otsuka M; Okamoto W; Fujisaka Y; Kaneda H; Tsurutani J; Nakagawa K
    Anticancer Res; 2012 May; 32(5):1805-9. PubMed ID: 22593465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with pain medication selection among patients diagnosed with diabetic peripheral neuropathic pain: a retrospective study.
    Chen S; Wu N; Boulanger L; Fraser K; Zhao Z; Zhao Y
    J Med Econ; 2011; 14(4):411-20. PubMed ID: 21615268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of treatment in diabetic peripheral neuropathic pain.
    Robinson-Papp J; Simpson DM
    Pain Med; 2007 Sep; 8 Suppl 2():S43-9. PubMed ID: 17714115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain.
    Yuen E; Gueorguieva I; Bueno-Burgos L; Iyengar S; Aarons L
    Eur J Pain; 2013 Mar; 17(3):382-93. PubMed ID: 22893563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the treatment and management of diabetic peripheral neuropathy.
    Donnan J; Ledger S
    CANNT J; 2006; 16(4):32-6; quiz 37-8. PubMed ID: 17252899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Average daily dose, medication adherence, and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine.
    Wu N; Chen S; Boulanger L; Rao P; Zhao Y
    Curr Med Res Opin; 2011 Jun; 27(6):1131-9. PubMed ID: 21456939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Controlled-release oxycodone -- a therapeutic option for severe neuropathic pain].
    Wörz R; Frank M; Achenbach U
    MMW Fortschr Med; 2003 Sep; 145(39):45. PubMed ID: 14649073
    [No Abstract]   [Full Text] [Related]  

  • 34. Treating diabetic peripheral neuropathic pain.
    Lindsay TJ; Rodgers BC; Savath V; Hettinger K
    Am Fam Physician; 2010 Jul; 82(2):151-8. PubMed ID: 20642268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
    Ziegler D; Pritchett YL; Wang F; Desaiah D; Robinson MJ; Hall JA; Chappell AS
    Diabetes Care; 2007 Mar; 30(3):664-9. PubMed ID: 17327338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series.
    Karanikolas M; Aretha D; Kiekkas P; Monantera G; Tsolakis I; Filos KS
    J Clin Pharm Ther; 2010 Oct; 35(5):603-8. PubMed ID: 20831684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
    Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
    BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacologic therapy in peripheral diabetic polyneuropathy].
    Mihai B; Lăcătuşu C; Graur M; Cijevschi-Prelipcean C; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):332-41. PubMed ID: 20700963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic management of diabetic peripheral neuropathic pain.
    Iyer S; Tanenberg RJ
    Expert Opin Pharmacother; 2013 Sep; 14(13):1765-75. PubMed ID: 23800105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
    Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
    Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.